These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

These five US stocks are defying market trends on new deals, technological breakthroughs, improved sectoral outlook, and ...

Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

Rhythm Pharmaceuticals met phase 3 endpoint for treating hypothalamic obesity, with regulatory submissions planned for 2025.

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

Rhythm Pharma (RYTM) stock rises as lead asset setmelanotide succeeds in a Phase 3 trial for a rare obesity type, causing an ...

Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% weight loss.

A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

Funds have also been suspended for AIDS Clinical Trial Group, a nearly 40-year-old system that has been responsible for key ...